相关实验视频

Updated: Jul 21, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

抑制GSK3β 改善动脉样硬化化

Xinjiang Cai¹, Yan Zhao¹, Yang Yang¹

¹Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA.

International journal of molecular sciences

|July 29, 2023

概括

抑制糖原合成酶激酶-3β (GSK3β) 通过改变β-catenin和SMAD1通路来减少动脉样硬化化. 这一发现为血管化提供了潜在的治疗策略.

科学领域:

心血管生物学心血管生物学
血管生物学血管生物学
分子医学是分子医学.

背景情况:

内皮-介质细胞过渡 (EndMT) 有助于动脉样硬化化.
糖原合成酶激酶-3β (GSK3β) 在调节细胞系和血管化方面发挥作用.
以前的研究表明,GSK3β抑制会影响β-catenin和SMAD1,影响骨质母细胞样细胞和血管化.

研究的目的:

研究GSK3β抑制在减少动脉样硬化化的作用.
为了确定GSK3β抑制是否影响动脉样硬化模型中的β-catenin和SMAD1通路.
探索GSK3β抑制对血管化的治疗潜力.

主要方法:

使用了动脉样硬化的小鼠模型 (Apoe淘汰赛小鼠).
服用GSK3β抑制剂和使用内皮特异性的GSK3β删除.
分析了大动脉组织中的分子变化,重点关注β-catenin和SMAD1表达.

主要成果:

在Apoe淘汰赛小鼠中,GSK3β抑制显著降低了动脉样硬化化.
固体内皮特异性去除GSK3β也减少了动脉样硬化化.
在主动脉中,GSK3β抑制调节了β-catenin和SMAD1水平,类似于Mgp缺乏小鼠的发现.

结论:

抑制GSK3β是一种可行的策略,可以减少动脉样硬化化.
该机制涉及β-catenin和SMAD1通路的调节,将细胞重定向到内皮细胞系.
这种方法对治疗动脉样硬化中的血管化有希望.

关键词:

动脉样硬化动脉样硬化糖原合成酶激酶-3ββ的作用.血管化血管化

更多相关视频

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Published on: January 27, 2023

相关概念视频

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...